Procaps Group S.A. (PROC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.01. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is PROC = $10 (+890.1% upside).
Financials: revenue is $410M, +8.6%/yr average growth. Net income is $43M, growing at -228.2%/yr. Net profit margin is 10.4% (healthy). Gross margin is 58.4% (+2.2 pp trend).
Balance sheet: total debt is $286M with negative equity of -$941,000 — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.81 (tight liquidity). Debt-to-assets is 62.1%. Total assets: $460M.
Analyst outlook: 0 / 1 analysts rate PROC as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 25/100 (Fail), Health 0/100 (Fail), Moat 58/100 (Partial), Future 52/100 (Partial), Income 55/100 (Partial).
